Introduction: In Burkina Faso, screening for hepatitis C virus in blood donations
is made using sensitive ELISA (Enzyme Linked Immuno Sorbent Assay)
type kits. However, no confirmation of the positive results obtained with
these kits is made before their notification to the blood donors due to the
high costs of the confirmation kits of immunoblots type. Objective: Evaluate
two rapid kits against one immunoblot kit in order to determine the most efficiency
which will be proposed as an alternative for the confirmation of
ELISA tests in the socio-economic context of Burkina Faso. Material and
Methods: The study was carried out using a panel of 72 sera, of which 22
were positive for anti-HCV antibodies and 50 were negative. The sera were
tested using the Monolisa® HCV Ag-Ab ULTRA kit and confirmed with the
DECISCAN HCV Plus kit. The panel was then tested with the SD BIOLINE
HCV kit and the HCV TRI-DOT kit and the results obtained were evaluated
against those of the DECISCAN HCV Plus kit used as “gold standard”. Results:
Compared to the DECISCAN HCV Plus kit, the HCV TRI-DOT kit exhibited
a sensitivity and specificity of 100% and the SD BIOLINE HCV kit a
sensitivity of 86.36% and a specificity of 100%. Conclusion: Based on the results
recorded by the HCV TRI-DOT kit, it would be best suited to the sero-epidemiological context of blood donors from the National Blood Transfusion
Center and could be proposed as an alternative for confirmation of
ELISA tests.